The present invention provides methods for treating cancer using GRK2 inhibitors such as small molecule inhibitors of GRK2 among others. The invention also features compositions containing GRK2 inhibitors, methods of diagnosing patients with GRK2-associated cancer and methods of predicting the response of cancer in a subject to treatment with GRK2 inhibitors.

The present invention discloses a method for diagnosing cancer comprising a step of detecting active protein kinase Cα in urine.

As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).

U biosensors, and related U-sensing genetic molecular components, genetic circuits, compositions, methods and systems are described, which in several embodiments can be used to detect and/or neutralize uranium and in particular bioavailable U.

The present invention provides improved DNA polymerases, in particular, type A DNA polymerases, that may be better suited for applications in recombinant DNA technologies. Among other things, the present invention provides modified DNA polymerases derived from directed evolution experiments designed to select mutations that confer advantageous phenotypes under conditions used in industrial or research applications.

A detection method of a target molecule in a specimen includes a (target molecule)-(labeled binding molecule)-(capturing molecule) complex forming step of reacting the target molecule in the specimen, a capturing molecule that binds to the target molecule, and a labeled binding molecule that binds to the target molecule and which is labeled with an enzyme that catalyzes a reaction to produce ATP, to form a complex formed of the target molecule, the capturing molecule, and the labeled binding molecule, a step of removing the labeled binding molecules which did not bind to the target molecule, an ATP production step of producing ATP by reacting the (target molecule)-(labeled binding molecule)-(capturing molecule) complex with a substrate of the enzyme that catalyzes a reaction to produce ATP, an ATP amplification step of amplifying the produced ATP, and an ATP detection step of detecting the amplified ATP.

The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

The present invention provides a method for screening for a telomerase reverse transcriptase (TERT) phosphorylation inhibitor using TERT or a fragment thereof, and a TERT kinase.

Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemotherapeutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.

Provided by the present disclosure are fluorescent proteins that can detect kinase activity. The fluorescent proteins of the present disclosure have us in, for example, detecting kinase activity in any eukaryotic cell.